Definition And Pathophysiology

  • Represents modified and purified toxin.
  • Classified as inactivated vaccine.
  • Requires multiple divided doses to decrease adverse effects and elicit high antibody titers.
  • Demonstrates inability to eliminate Corynebacterium diphtheriae from skin or nasopharynx.
  • Does not to provide permanent immunity.
  • Waning immunity necessitates regular booster doses.

Immunogenicity And Protection

  • Protective antibody titer defined as greater than 0.1 IU/mL.
  • Primary immunization series induces satisfactory immune response in 95-100% of infants.
  • Demonstrates 87% effectiveness against symptomatic disease.
  • Shows 81% effectiveness in preventing severe disease.
  • Confers 93% effectiveness against mortality.

Formulations And Antigen Content

  • Standard pediatric vaccines (DTwP, DTaP, DT) contain 20-30 limit of flocculation (Lf) units.
  • Standard dose DT shows more immunogenicity and less reactogenicity than conventional DTP.
  • Reactogenicity increases significantly with advancing age.
  • Reduced antigen formulations (Td, Tdap) contain smaller amounts (2 Lf units) of diphtheria toxoid.
  • Reduced formulations exclusively utilized beyond 7 years of age.
  • Available in multivalent combinations including Pentavalent and Hexavalent preparations.

Dosage, Route, And Storage

ParameterRecommendation
Volume0.5 mL.
RouteIntramuscular injection.
Site (Infants)Anterolateral aspect of mid-thigh.
Site (Older Children/Adults)Deltoid muscle.
TemperatureMaintain between 2-8°C.
Environmental PrecautionsProtect from light and never freeze.

Immunization Schedule

Primary Series And Pediatric Boosters

  • Administer primary doses at 6, 10, and 14 weeks.
  • Administer first booster at 15-18 months.
  • Administer second booster at 4-6 years.
  • Standard formulations contraindicated beyond 7 years of age.

Catch-Up Vaccination

  • Under 7 years: Administer DTwP or DTaP at 0, 1, and 6 months.
  • Above 7 years: Administer Tdap for first dose, followed by Td at 1 and 6 months.

Adolescent And Adult Schedule

  • Administer Tdap or Td booster at 10-12 years.
  • Provide decennial Td or Tdap boosters throughout life.
  • Provide single Tdap or Td dose during each pregnancy, preferably between 27 and 36 weeks gestation.

Adverse Effects And Contraindications

Common Reactions

  • Local pain, redness, and swelling frequently reported.
  • Systemic reactions include fever, anorexia, fussiness, and vomiting.
  • Administration of excessive toxoid doses leads to severe local immune complex-mediated Arthus reaction.

Contraindications

  • Absolute contraindication includes severe allergic reaction or anaphylaxis to previous dose.
  • Progressive neurological disease forms relative contraindication for pertussis-containing combinations, warranting DT utilization instead.